Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Eli Lilly and Company
  6. News
  7. Summary
    LLY   US5324571083

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  05/20 04:04:08 pm EDT
298.85 USD   +4.39%
05/20Eli Lilly, Incyte Say EMA Committee Recommends Approval of Alopecia Areata Drug Candidate
MT
05/20Lilly and Incyte's Olumiant Gets CHMP Recommendation in Alopecia Areata
DJ
05/16Lilly to Participate in UBS Global Healthcare Conference 2022
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Berenberg Bank Adjusts Eli Lilly and Company PT to $305 From $270, Maintains Buy Rating

12/20/2021 | 08:22am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about ELI LILLY AND COMPANY
05/20Eli Lilly, Incyte Say EMA Committee Recommends Approval of Alopecia Areata Drug Candida..
MT
05/20Lilly and Incyte's Olumiant Gets CHMP Recommendation in Alopecia Areata
DJ
05/16Lilly to Participate in UBS Global Healthcare Conference 2022
PR
05/16Eli Lilly Says FDA Approves Mounjaro Injection to Control Diabetes; Shares Rise
MT
05/13FDA Approves Lilly's Mounjaro (Tirzepatide) Injection, the First and Only GIP and GLP-1..
CI
05/13FDA Approves Eli Lilly's Novel, Dual-Targeted Treatment for Type 2 Diabetes
MT
05/13Berenberg Bank Adjusts Eli Lilly's Price Target to $345 From $305, Maintains Buy Rating
MT
05/13ELI LILLY AND COMPANY : Ex-dividend day for
FA
05/11Eli Lilly and Incyte Say Olumiant, Their COVID-19 Treatment for Hospitalized Adults, Ap..
MT
05/11FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients
DJ
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 29 036 M - -
Net income 2022 6 997 M - -
Net Debt 2022 9 221 M - -
P/E ratio 2022 39,4x
Yield 2022 1,26%
Capitalization 269 B 269 B -
EV / Sales 2022 9,58x
EV / Sales 2023 9,07x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 298,85 $
Average target price 313,14 $
Spread / Average Target 4,78%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY8.19%269 013
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099